Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark

NEW YORK, June 29, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that patient enrollment in its proof-of-concept pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications has reached the halfway point. Consistent with prior guidance, the company anticipates reporting top-line results in the second half of 2015.

"The halfway point of our proof-of-concept study marks another important milestone in our efforts to advance an oral formulation of BuTab that will compare favorably with currently marketed formulations of buprenorphine," stated Sergio Traversa, CEO of Relmada Therapeutics.  "As a traditional tablet taken by mouth and passing down the intestinal tract where it will ultimately be absorbed, BuTab would represent an important advance in patient care and a significant commercial opportunity for Relmada. We look forward to reporting results from this study during the second half of 2015. "

The clinical study is designed to assess the safety, tolerability, and pharmacokinetics of BuTab in healthy subjects. Based on the underlying scientific rationale and the company's previously conducted successful preclinical work, the key objective of this study is to assess if buprenorphine can be delivered orally and reach safe and effective blood levels through the gastrointestinal route of administration. There are currently no commercially available oral formulations of buprenorphine that result in gastro-intestinal absorption. The data generated by this study will inform the design of subsequent clinical pharmacology studies for opioid dependence and potential regulatory filing for this indication along with the design of a Phase 3 study in chronic pain under the abbreviated 505(b)(2) regulatory pathway.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

This news release contains "forward-looking statements."  These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact
Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169
mbecker@relmada.com

Media Contact:
David Salisbury
Berry & Company Public Relations
Tel: 212-253-8881
dsalisbury@berrypr.com

Logo - https://photos.prnewswire.com/prnh/20150113/168770LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enrollment-in-relmada-therapeutics-proof-of-concept-clinical-study-for-novel-oral-formulations-of-buprenorphine-reaches-halfway-mark-300105906.html

SOURCE Relmada Therapeutics, Inc.